Pharmaceutical

Medexus Schedules Third Fiscal Quarter 2025 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host…

11 months ago

KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the…

11 months ago

Human Organs-on-Chips Market to Reach USD 1019 Million by 2031 | 31.2% CAGR Growth Forecast – Valuates Reports

BANGALORE, India, Jan. 31, 2025 /PRNewswire/ -- Human Organs-on-Chips Market is Segmented by Type (Brain-on-a-chip, Liver-on-a-chip, Kidney-on-a-chip, Lung-on-a-chip, Heart-on-a-chip, Intestine-on-a-chip,…

11 months ago

Driving Innovation and Collaboration: TransCelerate BioPharma Champions the Future of R&D

Organization highlights transformative approaches to clinical research, operational efficiency and patient-centric care at SCOPE US 2025 PHILADELPHIA, Jan. 31, 2025…

11 months ago

Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals Inc. (TSX: MDP) ("Medexus" or the "Company"),…

11 months ago

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a…

11 months ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval…

11 months ago

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company…

11 months ago

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…

11 months ago